| 3/21/2022 |
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins |
| 12/22/2021 |
Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection |
| 11/3/2021 |
Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms |
| 10/5/2021 |
Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation |
| 8/31/2021 |
Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence |
| 8/10/2021 |
Lumen Bioscience Teams with Google to Apply Machine Learning to Biologics Manufacturing |
| 7/12/2021 |
Lumen Bioscience Expands Biologics Manufacturing Capacity with Lease of Historic Seattle Bakery |
| 6/16/2021 |
Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease |
| 4/21/2021 |
Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team |
| 1/27/2021 |
Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform |
| 10/7/2020 |
Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors |
| 9/22/2020 |
Lumen Bioscience Awarded Federal Grant to Rapidly Develop Antibody-based Covid-19 Therapeutic |
